Trials / Completed
CompletedNCT03785925
A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer
A Phase 2, Single-Arm Study of Bempegaldesleukin (NKTR-214) in Combination With Nivolumab in Cisplatin Ineligible, Locally Advanced or Metastatic Urothelial Cancer Patients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 192 (actual)
- Sponsor
- Nektar Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the anti-tumor activity of bempegaldesleukin (NKTR-214) in combination with nivolumab by assessing the objective response rate (ORR) in cisplatin ineligible, locally advanced or metastatic urothelial cancer patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Bempegaldesleukin | Specified dose on specified days |
| BIOLOGICAL | Nivolumab | Specified dose on specified days |
Timeline
- Start date
- 2019-04-29
- Primary completion
- 2022-02-09
- Completion
- 2022-06-30
- First posted
- 2018-12-24
- Last updated
- 2023-03-28
- Results posted
- 2023-03-28
Locations
70 sites across 18 countries: United States, Argentina, Australia, Belgium, Canada, Finland, France, Germany, Greece, Israel, Italy, Mexico, Netherlands, Portugal, Russia, Spain, Turkey (Türkiye), United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03785925. Inclusion in this directory is not an endorsement.